NextGen Sciences to Develop and Validate Protein Biomarker Assays for Takeda Pharmaceuticals

Date Posted: Tuesday, February 02, 2010

The biomarker assays will be designed to target specific protein isoforms found in liver and muscle in multiple species, for use in preclinical studies, and will also be validated for use in clinical studies. NextGen Sciences’ Multiple Reaction Monitoring (MRM) protein assay platform is ideal for studies of this kind, which involve multiple isoforms and multiple species.

Dr Michael Pisano, CEO of NextGen Sciences, commented: “We are delighted to have been chosen for this project and look forward to working closely with Takeda’s scientists in Japan.”

Further Information: http://www.nextgensciences.com

Related news from our archive

NextGen Sciences and Expression Pathology Develop Quantitative Protein Biomarker Assay
The protein biomarker assay methodology is designed to provide quantitative measurement of protein expression in FFPE tissue samples.

NextGen Sciences Divests Electrophoresis Business to Sigma-Aldrich
The deal involves the acquisition of the automated gel casting unit and the range of premium large format pre-cast gels to Sigma-Aldrich Corporation.

NextGen Sciences Divests Automation and Software Business to Focus on Protein Biomarker Services
Company sells its ‘gene to protein’ automation and software business to a management led spin-out called eXeTek Ltd.

NextGen Sciences Announces Commercial Alliance with Paragon Bioservices
The alliance expands the portfolio of both companies with the ability to offer customers an integrated offering including molecular biology, proteomics and biomarker discovery.